Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
CNC's improving Medicaid margins, stronger Marketplace profitability and earnings recovery support its valuation, but sustainability remains the key test.
CNC - Centene Corp.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$68.29
DETAILS
HIGH:
$80.00
LOW:
$39.00
MEDIAN:
$70.00
CONSENSUS:
$68.29
UPSIDE:
5.08%
Stock News
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
The new partnership will provide eligible members with $0 primary care visits, lab services, and virtual care beginning in 2027 ST. LOUIS, Oct. 7, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), through Ambetter Health Solutions, today announced a new collaboration with Marathon Health, a leading advanced primary care provider, designed to make primary care easier to access for Ambetter members in select counties across Indiana and Missouri.
Buy 5 Growth Stocks to Boost Your Portfolio in Q4 After a Mixed Q3
PWR, FORM, SMTC, CNC and ROKU offer strong growth prospects in Q4, driven by AI demand, estimate gains, healthcare momentum and streaming growth.
Are Investors Undervaluing Centene (CNC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Growth Stocks to Buy for October 1st
CNC, ATI and BP made it to the Zacks Rank #1 (Strong Buy) growth stocks list on October 1, 2026.
Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care
2027 Wellcare portfolio brings together affordable Medicare coverage and innovative supplemental benefits combined with the nation's largest standalone Medicare Part D platform Provides coordinated Medicare-Medicaid solutions for dual-eligible members ST. LOUIS, Oct. 1, 2026 /PRNewswire/ -- Wellcare, the Medicare brand of Centene Corporation (NYSE: CNC), today announced its 2027 Medicare Advantage (MA) and Prescription Drug Plan (PDP) offerings ahead of the Medicare Annual Enrollment Period (AEP), which begins Oct. 15 and runs through Dec. 7.
5 Low P/B Stocks With Attractive Value and Strong Growth Potential
BMA, CNC, ENS, ROCK and KMT stand out among low P/B stocks, with strong Value Scores and projected 3-5-year EPS growth of up to 32.4%.
Best Growth Stocks to Buy for September 29th
CNC, MNDY and ATI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 29, 2026.
Here's Why Centene (CNC) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Best Growth Stocks to Buy for September 24th
NESR, BEKE and CNC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 24th, 2026.
Health Net Providing Special Assistance to Members and Providers Affected by Weather Events Statewide and Robin Lane Sewage Spill in Lake County
SACRAMENTO, Calif., Sept. 22, 2026 /PRNewswire/ -- Following Gov.
Stockton Seniors Gain Access to 76 Affordable Homes with Health Net's $3 Million Investment
Mutual Housing California's Fairview Terrace will help income-qualified older adults in San Joaquin County find stable, affordable housing and remain connected to the community they call home STOCKTON, Calif., Sept. 16, 2026 /PRNewswire/ -- Health Net, one of California's most experienced Medi-Cal managed care health plans and company of Centene Corporation (NYSE: CNC), announced a $3 million grant to Mutual Housing California to support the development of Fairview Terrace, a new affordable housing community for income-qualified seniors in Stockton.
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
Here is how Centene (CNC) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
3 Momentum Anomaly Stocks to Buy as Markets Surge on AI Rally
Centene, BrightSpring and Delek combine 52-week gains with short-term pullbacks, putting them in focus as momentum plays for volatile markets.
How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet
Centene's robust cash flow is helping cut debt, with a lower debt-to-capital ratio and added liquidity reshaping its balance sheet.
Best Growth Stocks to Buy for September 22nd
ATI, BEKE and CNC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 22nd, 2026.
Centene (CNC) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene Reaffirms 2026 EPS Outlook as Medicaid Membership Decline Deepens
Centene NYSE: CNC reaffirmed its 2026 adjusted diluted earnings-per-share guidance of more than $4.80 at the Deutsche Bank Healthcare Summit, with Chief Executive Officer Sarah London saying the company's performance through the first two months of the third quarter was in line with expectations.
Employer Health Costs Surge: What it Means for EHTH, CNC & UNH
eHealth says surging 2027 health costs are pushing smaller employers toward ICHRAs, potentially expanding individual coverage demand.
Is Centene (CNC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Price Targets
Bernstein SocGen Group Reiterates Outperform Rating on Centene (CNC), discusses CFO change
$79.00
(was $64.43)
UBS
Argus Upgrades Centene (CNC) to Buy
$80.00
(was $66.56)
John Staszak
·
Argus Research
Centene price target raised to $79 from $68 at Bernstein
$79.00
(was $62.37)
Bernstein
Centene (CNC) PT Raised to $79 at Bernstein SocGen Group
$79.00
(was $62.22)
Stifel Nicolaus
Centene price target raised to $66 from $57 at Morgan Stanley
$66.00
(was $62.27)
Erin Wright
·
Morgan Stanley
Centene price target raised to $66 from $46 at Baird
$66.00
(was $64.02)
Robert W. Baird
Centene price target raised to $80 from $75 at Barclays
$80.00
(was $64.02)
Andrew Mok
·
Barclays
Centene price target raised to $78 from $71 at Truist
$78.00
(was $68.29)
David MacDonald
·
Truist Financial
Centene price target raised to $69 from $56 at Wells Fargo
$69.00
(was $67.35)
Wells Fargo
Centene price target raised to $75 from $60 at Cantor Fitzgerald
$75.00
(was $66.05)
Sarah James
·
Raymond James
Centene initiated with a Sector Perform at RBC Capital
$70.00
(was $63.67)
Ben Hendrix
·
RBC Capital
Centene price target raised to $63 from $58 at Mizuho
$63.00
(was $62.33)
Mizuho Securities
Centene price target raised to $57 from $50 at Morgan Stanley
$57.00
(was $59.55)
Erin Wright
·
Morgan Stanley
Centene price target raised to $71 from $58 at Truist
$71.00
(was $59.59)
Truist Financial
Centene price target raised to $75 from $63 at Barclays
$75.00
(was $57.65)
Barclays
Centene price target raised to $61 from $55 at UBS
$61.00
(was $57.77)
UBS
Centene price target raised to $58 from $50 at Mizuho
$58.00
(was $59.15)
Ann Hynes
·
Mizuho Securities
Centene upgraded to Buy from Hold at Deutsche Bank
$80.00
(was $59.15)
Deutsche Bank
Centene price target raised to $58 from $49 at Truist
$58.00
(was $52.69)
Truist Financial
Centene price target raised to $58 from $45 at Oppenheimer
$58.00
(was $49.57)
Oppenheimer